Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Stock Short Interest Rises 134.8%

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totaling 580 shares, an increase of 134.8% from the September 30th total of 247 shares. Based on an average daily trading volume, of 1,840 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.0% of the company’s shares are short sold.

Molecular Partners Stock Up 2.5%

Shares of MOLN opened at $3.62 on Friday. The stock’s fifty day simple moving average is $4.03 and its 200-day simple moving average is $4.18. Molecular Partners has a 12-month low of $3.51 and a 12-month high of $5.36. The firm has a market capitalization of $146.18 million, a PE ratio of -2.15 and a beta of 1.11.

Molecular Partners (NASDAQ:MOLN) last issued its earnings results on Thursday, October 29th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.08. Analysts anticipate that Molecular Partners will post -1.28 EPS for the current year.

Analyst Ratings Changes

MOLN has been the subject of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a report on Friday, October 2nd. HC Wainwright reiterated a “buy” rating on shares of Molecular Partners in a research note on Monday, July 6th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Molecular Partners currently has an average rating of “Hold” and a consensus target price of $8.38.

About Molecular Partners

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland. The company develops therapeutic molecules based on its proprietary DARPin platform, which uses designed ankyrin repeat proteins to create targeted, multi-specific medicines intended to address complex disease pathways.

Molecular Partners’ research and development activities have focused primarily on oncology, ophthalmology and infectious diseases. Its pipeline has included experimental programs designed to engage multiple biological targets, with the goal of improving treatment effectiveness and addressing limitations associated with conventional antibody-based therapies.